272
Views
3
CrossRef citations to date
0
Altmetric
Drug Profile

Intravenous carbamazepine: a new formulation of a familiar drug

&
Pages 851-860 | Received 17 May 2017, Accepted 04 Aug 2017, Published online: 16 Aug 2017

References

  • Vajda FJ, Eadie MJ. The clinical pharmacology of traditional antiepileptic drugs. Epileptic Disord. 2014;16(4):395–408.
  • WHO model list of essential medicines. 2015 [cited 2017 Jan 30]. Available from: http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1
  • Arzimanoglou A, Ben-Menachem E, Cramer J, et al. The evolution of antiepileptic drug development and regulation. Epileptic Disord. 2010;12(1):3–15.
  • Jost J, Preux PM, Druet-Cabanac M, et al. How to reduce the treatment gap for people with epilepsy in resource-limited settings by innovative galenic formulations: a review of the current situation, overview of potential techniques, interests and limits. Epilepsy Res. 2016;119:49–61.
  • Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68(6):402–408.
  • Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58:522–530.
  • WHO Epilepsy Fact Sheet. 2017 [cited 2017 Mar 24]. Available from: http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1.
  • Conway JM, White JR, Birnbaum AK, et al. Safety of an IV formulation of carbamazepine. Epilepsy Res. 2009;84(2–3):242–244.
  • Marino SE, Birnbaum AK, Leppik IE, et al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther. 2012;91(3):483–488.
  • Shorvon S. Handbook of epilepsy treatment. Oxford, UK: Wiley-Blackwell. 2011. p. 365–377.
  • Patel SI, Birnbaum AK, Cloyd JC, et al. Intravenous and intramuscular formulations of antiseizure drugs in the treatment of epilepsy. CNS Drugs. 2015;29(12):1009–1022.
  • Trinka E, Kalviainen R. 25 years of advances in the definition, classification and treatment of status epilepticus. Seizure. 2017;44:65–73.
  • Established Status Epilepticus Treatment Trial (ESETT). (NCT01960075). [cited 2017 Mar 24]. Available from: https://clinicaltrials.gov/ct2/show/NCT01960075?term=NCT01960075&rank=1.
  • Alrashood ST. Carbamazepine. Profiles Drug Subst Excip Relat Methodol. 2016;41:133–321.
  • Willow M, Kuenzel EA, Catterall WA. Inhibition of voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol. 1984;25(2):228–234.
  • Majkowski J, Dlawichowska E, Sobieszek A. Carbamazepine effects on afterdischarge, memory retrieval, and conditioned avoidance response latency in hippocampally kindled cats. Epilepsia. 1994;35(1):209–215.
  • Quattrone A, Crunelli V, Samanin R. Seizure susceptibility and anticonvulsant activity of carbamazepine, diphenylhydantoin and phenobarbital in rats with selective depletions of brain monoamines. Neuropharmacology. 1978;17(8):643–647.
  • Quattrone A, Samanin R. Decreased anticonvulsant activity of carbamazepine in 6-hydroxydopamine-treated rats. Eur J Pharmacol. 1977;41(3):336–336.
  • Wada JA, Sato M, Wake A, et al. Prophylactic effects of phenytoin, phenobarbital, and carbamazepine examined in kindling cat preparations. Arch Neurol. 1976;33(6):426–434.
  • Czuczwar SJ, Turski L, Kleinrok Z. Anticonvulsant action of phenobarbital, diazepam, carbamazepine, and diphenylhydantoin in the electroshock test in mice after lesion of hippocampal pyramidal cells with intracerebroventricular kainic acid. Epilepsia. 1982;23(4):377–382.
  • Bourgeois BF, Wad N. Individual and combined antiepileptic and neurotoxic activity of carbamazepine and carbamazepine-10,11-epoxide in mice. J Pharmacol Exp Ther. 1984;231(2):411–415.
  • Gilbert TH, Teskey GC. Conventional anticonvulsant drugs in the guinea-pig kindling model of partial seizures: effects of acute carbamazepine. Exp Brain Res. 2001;140(4):479–485.
  • Geradin AP, Abadie FV, Campestrini JA, et al. Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses. J Pharmacokinet Biopharm. 1976;4(6):521–535.
  • Bertilsson L, Hojer B, Tybring G, et al. Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin Pharmacol Ther. 1980;27(1):83–88.
  • Eichelbaum M, Ekbom K, Bertilsson L, et al. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol. 1975;8(5):337–341.
  • Levy RH, Lockard JS, Green JR, et al. Pharmacokinetics of carbamazepine in monkeys following intravenous and oral administration. J Pharm Sci. 1975;64(2):302–307.
  • Pitlick WH, Levy RH. Time-dependent kinetics I: exponential autoinduction of carbamazepine in monkeys. J Pharm Sci. 1977;66(5):647–649.
  • Bourgeois BF, Wad N. Carbamazepine-10,11-diol steady-state serum levels and renal excretion during carbamazepine therapy in adults and children. Ther Drug Monit. 1984;6(3):259–265.
  • Burianova I, Borecka K. Routine therapeutic monitoring of the active metabolite of carbamazepine: is it really necessary? Clin Biochem. 2015;48(13–14):866–869.
  • Brodie MJ, Mintzer S, Pack AM, et al. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54(1):11–27.
  • Tegretol (carbamazepine) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2013.
  • Besag FM, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Saf. 2006;29(2):95–118.
  • Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol. 1998;54(8):639–643.
  • Mula M. Anticonvulsants - antidepressants pharmacokinetic drug interactions: the role of the CYP450 system in psychopharmacology. Curr Drug Metab. 2008;9(8):730–737.
  • Bertilsson L. Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet. 1978;3(2):128–143.
  • Strack DK, Leckband SG, Meyer JM. Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine. J Psychiatr Pract. 2009;15(6):442–448.
  • Punyawudho B, Cloyd JC, Leppik IE, et al. Characterization of the time course of carbamazepine deinduction by an enzyme turnover model. Clin Pharmacokinet. 2009;48(5):313–320.
  • Luke DR, Tomaszewski K, Damle B, et al. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci. 2010;99(8):3291–3301.
  • Abel S, Allan R, Gandelman K, et al. Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies. Clin Drug Investig. 2008;28(7):409–420.
  • Luke DR, Wood ND, Tomaszewski KE, et al. Pharmacokinetics of sulfobutylether-beta-cyclodextrin (SBECD) in subjects on hemodialysis. Nephrol Dial Transplant. 2012;27(3):1207–1212.
  • Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 1989;3(1):70–76.
  • Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med. 1992;327(11):765–771.
  • Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;313(3):145–151.
  • Ramsay RE, Wilder BJ, Berger JR, et al. A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology. 1983;33(7):904–910.
  • Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet (London, England). 1995;345(8948):476–479.
  • Brodie MJ, Wroe SJ, Dean AD, et al. Efficacy and safety of remacemide versus carbamazepine in newly diagnosed epilepsy: comparison by sequential analysis. E&B. 2002;3(2):140–146.
  • Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet (London, England). 1999;354(9172):13–19.
  • Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. 2003;107(3):165–175.
  • Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Canadian Study Group for Childhood Epilepsy. Epilepsia. 1998;39(9):952–959.
  • Wheless JW, Neto W, Wang S. Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy. J Child Neurol. 2004;19(2):135–141.
  • Tolbert D, Cloyd J, Biton V, et al. Bioequivalence of oral and intravenous carbamazepine formulations in adult patients with epilepsy. Epilepsia. 2015;56(6):915–923.
  • Lee D, Kalu U, Halford JJ, et al. Intravenous carbamazepine as short-term replacement therapy for oral carbamazepine in adults with epilepsy: pooled tolerability results from two open-label trials. Epilepsia. 2015;56(6):906–914.
  • Schoeman JF, Elyas AA, Brett EM, et al. Correlation between plasma carbamazepine-10,11-epoxide concentration and drug side-effects in children with epilepsy. Dev Med Child Neurol. 1984;26(6):756–764.
  • Clark AM, Kriel RL, Leppik IE, et al. Intravenous topiramate: comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers. Epilepsia. 2013;54(6):1099–1105.
  • Clark AM, Kriel RL, Leppik IE, et al. Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate. Epilepsia. 2013;54(6):1106–1111.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.